Recruiting Multiple Myeloma Studies in Detroit
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs ...
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (M...
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high d...
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab...
Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant \[AS...
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body'...
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigato...
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM)....
About Multiple Myeloma Clinical Trials in Detroit
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 8 multiple myeloma clinical trials recruiting participants in Detroit, MICHIGAN. These studies are seeking a combined 1,064 participants. Research is being sponsored by Regeneron Pharmaceuticals, Multiple Myeloma Research Consortium, Pfizer and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Detroit — FAQ
Are there multiple myeloma clinical trials in Detroit?
Yes, there are 8 multiple myeloma clinical trials currently recruiting in Detroit, MICHIGAN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Detroit?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Detroit research site will contact you about next steps.
Are clinical trials in Detroit free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Detroit studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 8 active trials in Detroit are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov